Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 383-392 , March 2010

Congestion as a Therapeutic Target in Acute Heart Failure Syndromes

  • Steven R. Goldsmith

      Affiliations

    • Cardiology Division, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN 55415
    • Corresponding Author InformationAddress reprint requests to Steven R. Goldsmith, MD, Hennepin County Medical Center, 701 Park Ave, Minneapolis, MN 55415.
    • ,
  • Filippo Brandimarte

      Affiliations

    • Department Cardiovascular, Respiratory and Morphological Sciences, Sapienza University, Rome, Italy
    • ,
  • Mihai Gheorghiade

      Affiliations

    • Cardiology Division, Northwestern University, Chicago, IL

References 

  1. Gheorghiade M, Zannad F, Sopko G, et al. International Working Group on Acute heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  2. Adams KF, Yddin N, Patterson JH. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117–2126
  3. Klein L, Massie BM, Leimberger JD, et al. Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1:25–33
  4. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67
  5. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–683
  6. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  7. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226
  8. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179–185
  9. Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J Am Coll Cardiol. 2004;44:1308–1310
  10. Hasselblad V, Gattis SW, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–1069
  11. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart. 1996;75:349–351
  12. Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology. 2001;96:144–154
  13. Marenzi G, Lauri G, Grazi M, et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–968
  14. Rimondini A, Cipolla C, Della Bella P, et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987;83:43–48
  15. Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003;9:227–231
  16. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–2046
  17. Bart BA, Fang JC, Guglin M, et al. Changes in GFR, BUN and BUN/creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics. J Am Coll Cardiol. 2008;51(10 Suppl A):A48
  18. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema. Lancet. 1988;1:1033–1035
  19. Bart BA, Goldsmith SR, Boyle A. Improvement in cardiorenal syndrome with ultrafiltration. J Card Fail. 2009;[in press]
  20. Bart BA, Insel J, Goldstein MM, et al. The improved outcomes following ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to increased weight loss in the ultrafiltration group. J Cardiac Fail. 2007;13(Suppl 2):S188
  21. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29:1–9
  22. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–1331
  23. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332–1343
  24. Gheorghiade M, Gattis WA, O'connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  25. Goldsmith SR, Haught H, Barve A, et al. Efficacy and safety of conivaptan in acute decompensated heart failure, a dose ranging pilot study. Heart Fail Rev. 2009;14:1382–4147
  26. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6
  27. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  28. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540–1545
  29. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–F278
  30. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007;9:82–86
  31. Weihprecht H, Lorenz JN, Briggs JP, et al. Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am J Physiol. 1994;266(2 Pt 2):F227–F239
  32. Thomson S, Bao D, Deng A, et al. Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback. J Clin Invest. 2000;106:289–298
  33. Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007;13:609–617
  34. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551–1560
  35. Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol. 2007;50:600–606
  36. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  37. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol. 2000;35:56–59
  38. Metra MOC, Massie B, Cotter G, et al. PROTECT Study: effects of rolofylline in patients with acute heart failue syndrome and renal impairment. Eur Heart J. 2009;
  39. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393
  40. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  41. Gheorghiade M, Gattis SW, Adams KF, et al. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol. 2005;96:18G–25G
  42. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  43. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  44. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009–2019
  45. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429–1439
  46. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  47. Mebazaa A, Nieminen M, Packer M, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: the SURVIVE randomized trial. JAMA. 2007;297:1883–1891
  48. Packer M, Colucci WS, Fisher L, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. J Card Fail. 2003;9:S61
  49. Packer M. The Rancomized multicenter EValuation of Intraveneous leVosimendan Efficacy-2 (REVIVE-2) trial. Late breaking clinical trials. In: American Heart Association, Annual Scientific Session, Dallas TX, November 13-16, 2005. 2005;
  50. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003
  51. Costello-Boerrigter LC, Boerrigter G, Harty GJ, et al. Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure. J Card Fail. 2007;S144
  52. Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation. 2008;117:200–205
  53. Lisy O, Huntley BK, McCormick DJ, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–68
  54. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136–2144
  55. Ghali JK, Smith WB, Torre-Amione G, et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol. 2007;47A–56A
  56. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276–2285
  57. Hermiller JB, Magorien RD, Leithe ME, et al. Clonidine in congestive heart failure: a vasodilator with negative inotropic effects. Am J Cardiol. 1983;51:791–795

 Statement of Conflict of Interest: see page 390.

PII: S0033-0620(09)00095-4

doi: 10.1016/j.pcad.2009.11.005

Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 383-392 , March 2010

Article Tools

* Image Usage & Resolution